PassFinals
Renal & Urology

Benign prostatic enlargement

Benign prostatic enlargement can narrow the bladder outlet and produce mixed lower urinary tract symptoms, but symptom severity, bladder function and complications—not prostate size alone—determine management.

In a nutshell

Benign prostatic enlargement can cause mixed lower urinary tract symptoms, but prostate size alone does not determine treatment. Assess symptom bother, urinalysis, DRE and cancer risk; use PSA after counselling when appropriate. Conservative care suits mild symptoms, alpha-blockers treat moderate-to-severe LUTS, 5-alpha-reductase inhibitors reduce progression risk in larger glands, and antimuscarinic or beta-3 treatment targets persistent storage symptoms.

Classic presentation

An older man with gradual hesitancy, weak stream, incomplete emptying, frequency and nocturia, often with a smooth enlarged prostate and no systemic illness.

Key points

  • Separate voiding symptoms from storage symptoms: they may have different causes and may respond to different treatments.
  • Use a validated symptom score such as IPSS and assess quality-of-life bother before starting treatment.
  • Offer urinalysis and discuss PSA when LUTS suggest benign enlargement, the prostate feels abnormal or cancer is a concern; PSA is non-specific.
  • Alpha-blockers are for moderate-to-severe LUTS; 5-alpha-reductase inhibitors are for a significantly enlarged prostate or raised PSA in men at high risk of progression.
  • Use a 5-alpha-reductase inhibitor or combination therapy only when the prostate is significantly enlarged or the PSA is raised and progression risk is high, following the current NICE thresholds.
  • For persistent storage symptoms, an antimuscarinic is first pharmacological choice; mirabegron or vibegron is an option when antimuscarinics are unsuitable, ineffective or poorly tolerated.
  • Acute retention needs immediate catheterisation; chronic retention with renal impairment or hydronephrosis needs drainage and urological assessment.
  • Severe or refractory symptoms, recurrent retention, infection, stones or obstructive renal impairment prompt surgical discussion.

First-line investigation

IPSS and symptom history, abdominal and DRE examination, urinalysis, and PSA discussion when appropriate; add creatinine, imaging, flow rate or residual measurement when red flags or specialist assessment indicate.

Management

Assess symptoms and red flags

  • Separate voiding and storage symptoms, assess bother and quality of life, perform abdominal and DRE examination, do urinalysis and discuss PSA when appropriate; investigate infection, cancer, polyuria, stricture and neurological or bladder causes when suggested.1,2

Use conservative care first when suitable

  • Offer lifestyle advice, bladder training for storage symptoms and active surveillance for mild or non-bothersome symptoms, with planned review and symptom tracking.1,2

Treat moderate-to-severe or progressive LUTS

  • Offer an alpha-blocker for moderate-to-severe LUTS; offer a 5-alpha-reductase inhibitor, alone or in combination, when the prostate is estimated larger than 30 g or PSA is greater than 1.4 ng/ml and progression risk is high.1,5

Target persistent storage symptoms

  • Offer an antimuscarinic for overactive-bladder-type storage symptoms; consider mirabegron or vibegron when antimuscarinics are unsuitable, ineffective or poorly tolerated, with residual-urine and adverse-effect review.1,4,3,5

Drain retention and protect the upper tracts

  • Immediately catheterise acute retention; in chronic retention assess residual, creatinine and upper-tract imaging, and drain when renal impairment or hydronephrosis is secondary to retention.1,2

Review and refer for surgery

  • Review response and adverse effects, and refer for urological surgical discussion when symptoms are severe or refractory, or when retention, recurrent infection, stones, haematuria or obstructive renal impairment develops.1,6

Exam traps

  • A high or rising PSA is not automatically BPH; consider infection, retention, instrumentation and prostate cancer.
  • A hard or irregular prostate is suspicious for malignancy, not typical benign enlargement.
  • Do not delay catheterisation in acute retention while waiting for a PSA, scan or specialist appointment.
  • Flow rate and post-void residual are specialist-assessment tests rather than routine initial tests in uncomplicated LUTS.
  • Antimuscarinics can worsen incomplete emptying and cause anticholinergic adverse effects; assess residual urine and risk before use.
  • Vibegron is now linked in current NICE CG97 through TA999; do not omit it when summarising beta-3 options.
  • PDE5 inhibitors should not be offered solely to treat LUTS except in a clinical trial under the current CG97 recommendation.

Illustrations

Prostate zonal anatomyDiagram of the prostate showing the transitional zone around the urethra, where benign hyperplasia develops, and the peripheral zone where most prostate cancers arise.Nevit Dilmen, Wikimedia Commons · CC0
Retention and upper-tract riskIllustration showing incomplete emptying progressing to chronic retention, bladder distension, hydronephrosis and renal impairment, with acute retention and renal-risk escalation highlighted.PassFinals · original

Key sources

  1. NICE CG97: Lower urinary tract symptoms in men—management, current recommendations and December 2024 review (NICE pathway for initial and specialist assessment, conservative care, drug treatment, surgery and acute or chronic urinary retention; last updated June 2015 and last reviewed December 2024.)
  2. NHS: Enlarged prostate (Current NHS information on symptoms, assessment, urgent inability to pass urine, lifestyle measures, medicines, catheterisation and surgery.)
  3. NICE TA999: Vibegron for treating symptoms of overactive bladder syndrome, September 2024 (Vibegron is an option when antimuscarinics are not suitable, ineffective or poorly tolerated, subject to the NICE recommendation.)
  4. NICE TA290: Mirabegron for treating symptoms of overactive bladder (Mirabegron is an option when antimuscarinics are contraindicated, ineffective or have unacceptable side effects.)
  5. BNF online: current prescribing information for medicines used in male LUTS and benign prostatic enlargement (Use the current BNF and local formulary for formulation-specific indications, contraindications, interactions, adverse effects and monitoring; no fixed dose is reproduced here.)
  6. NHS England: Decision support tool—making a decision about enlarged prostate (UK decision-support information for discussing procedure choices, expected benefits, risks and alternatives for enlarged prostate.)

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.